Pfizer Calls Out Kaiser Over Contradictory Neurontin Claims
Aiming to scuttle a $142 million jury award in multidistrict litigation over pain drug Neurontin, Pfizer Inc. on Tuesday sharply criticized Kaiser Foundation Health Plan Inc. before the First Circuit, accusing...To view the full article, register now.
Already a subscriber? Click here to view full article